Retrospective, Multicentric, Observational Study to Evaluate the Efficacy and Safety of the Combination of an Immune Checkpoint Inhibitor (ICI) and Radiotherapy (RT) in Patients With Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL)
Overview
- Phase
- N/A
- Intervention
- Immune checkpoint inhibitor
- Conditions
- Hodgkin Lymphoma
- Sponsor
- Ospedale Maggiore Di Trieste
- Enrollment
- 12
- Locations
- 1
- Primary Endpoint
- Complete remission (CR) rate measured according to Lugano and Lyric criteria by CT-PET (positron emission tomography / computer tomography) or CT (computer tomography) scan
- Last Updated
- 5 years ago
Overview
Brief Summary
This is an observational retrospective study to investigate the efficacy and safety of the treatment with an immune checkpoint inhibitor (nivolumab or pembrolizumab) in combination with radiotherapy in patients with relapsed/refractory classical Hodgkin lymphoma.
Detailed Description
In patients with relapsed/refractory Hodgkin lymphoma, treatment with immune checkpoint inhibitors (ICIs), nivolumab and pembrolizumab, leads to 20-30% of complete remission (CR) rate. This means that for the majority of patients a consolidation strategy is usually offered, in order to reduce relapse rate. Strategies to improve CR rates should therefore be implemented, including combination treatments. In solid tumors, the combination of ICIs and radiotherapy led to higher response rates without mjor toxicity concerns. Radiotherapy is an effective therapeutic option already used in Hodgkin lymphoma patients, also in the setting of relapsed/refractory disease. In his observational study we aim to evaluate the efficacy and safety of ICIs and radiotherapy administered in combination in patients with relapsed/refractory Hodgkin lymphoma.
Investigators
Francesco Zaja
Professor
Ospedale Maggiore Di Trieste
Eligibility Criteria
Inclusion Criteria
- •age ≥18 years
- •diagnosis of classical Hodgkin lymphoma, treated with one immune checkpoint inhibitor (ICI) (nivolumab or pembrolizumab), as per label indication
- •having received a concomitant radiotherapy, as per clinical need (persistence of localized disease, bulky disease, other reasons). "Concomitant" radiotherapy means a treatment received during the administration of ICI, or during the 8 weeks that precede or follow the start or the end of the treatment with ICI
Exclusion Criteria
- •Having received a treatment with an ICI and radiotherapy not "concomitant", according to the abovementioned definition
- •Having received any other anti-lymphoma treatments during the same period of time
- •Patients who have not been evaluated by CT-PET or CT at the end of the combination therapy
Arms & Interventions
treated patients
patients with relapsed/refractory Hodgkin lymphoma who received a treatment with the combination of radiotherapy and an immune checkpoint inhibitor
Intervention: Immune checkpoint inhibitor
Outcomes
Primary Outcomes
Complete remission (CR) rate measured according to Lugano and Lyric criteria by CT-PET (positron emission tomography / computer tomography) or CT (computer tomography) scan
Time Frame: up to 2 months after the end of ICI or 3 months after the end of RT
Secondary Outcomes
- overall response rate (ORR) measured according to Lugano and Lyric criteria by CT-PET or CT scan(up to 2 months after the end of ICI or 3 months after the end of RT)
- safety profile assessed by monitoring adverse events (AEs) and serious adverse events (SAEs) according to CTCAE v. 4.0(through study completion, for an average of 1 year)
- progression-free survival (PFS) measured according to Cheson 2007 response criteria(from the start of the treatment until the date of documented progression or date of death from any cause, assessed up to 5 years)